Genocea Biosciences Inc. (NASDAQ:GNCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “
Several other research analysts have also commented on the stock. Piper Jaffray Cos. reduced their price objective on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, September 29th. FBR & Co reiterated a “buy” rating on shares of Genocea Biosciences in a research note on Monday, August 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Genocea Biosciences in a research note on Thursday, November 3rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $12.35.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded up 0.23% during mid-day trading on Tuesday, hitting $4.32. 15,884 shares of the stock traded hands. Genocea Biosciences has a 12 month low of $2.56 and a 12 month high of $8.07. The firm has a 50 day moving average of $3.96 and a 200 day moving average of $4.43. The stock’s market cap is $122.60 million.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.01. Genocea Biosciences had a negative return on equity of 57.92% and a negative net margin of 5,121.17%. On average, equities analysts expect that Genocea Biosciences will post ($1.64) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of GNCA. Northern Trust Corp raised its position in shares of Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock worth $177,000 after buying an additional 6,763 shares during the last quarter. Northpointe Capital LLC increased its stake in Genocea Biosciences by 90.2% in the third quarter. Northpointe Capital LLC now owns 1,438,286 shares of the company’s stock valued at $7,364,000 after buying an additional 682,269 shares during the period. Paloma Partners Management Co acquired a new stake in Genocea Biosciences during the second quarter valued at approximately $334,000. Alpine Partners VI LLC acquired a new stake in Genocea Biosciences during the second quarter valued at approximately $120,000. Finally, TFS Capital LLC acquired a new stake in Genocea Biosciences during the second quarter valued at approximately $133,000. Institutional investors and hedge funds own 58.67% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.